Vascular Pharmaceuticals, Inc. is focused on the development and commercialization of novel therapeutics targeting the treatment of diabetes associate

Founded in 2005 by Dr. David R. Clemmons, Chief of the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, the company has three active research programs focused on diabetic atherosclerosis, retinopathy and obesity. Vascular Pharma's lead compound is a therapeutic antibody currently undergoing humanization that offers a novel approach to antagonize a signaling pathway implicated in atherosclerosis development in diabetics. Our lead product candida...

Founded in 2005 by Dr. David R. Clemmons, Chief of the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, the company has three active research programs focused on diabetic atherosclerosis, retinopathy and obesity. Vascular Pharma's lead compound is a therapeutic antibody currently undergoing humanization that offers a novel approach to antagonize a signaling pathway implicated in atherosclerosis development in diabetics. Our lead product candidate works in the insulin-like growth factor-I (IGF-1) signaling pathway. It binds to a unique site on the aVB3 receptor and inhibits IGF-1 mediated smooth muscle cell proliferation stimulated by hyperglycemia